AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15530758 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 11765143 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule formulation (500 mg sitafloxacin)
Number of subjects: 0
Study 11765143 — intervention group
Group type: COMPARATOR
Intervention: Intravenous formulation (400 mg sitafloxacin)
Number of subjects: 0
Study 9267668 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 170 mg/m2 and Cyclophosphamide 2 gm/m2
Number of subjects: 141
Study 9267668 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2 and Cyclophosphamide 3 gm/m2
Number of subjects: 141
Study 9267668 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior chemotherapy regimen (1 vs more than 1)
Number of subjects: 141
Study 9267668 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior radiation therapy
Number of subjects: 141
Study 9267668 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient performance status
Number of subjects: 141
Study 8488991 — intervention group
Group type: EXPERIMENTAL
Intervention: etomidate in lipid emulsion formulation (Lipofundin MCT 20%; eto-lip)
Number of subjects: 100
Study 8488991 — intervention group
Group type: COMPARATOR
Intervention: etomidate in propylene glycol 35% (eto-pg)
Number of subjects: 100
Study 3449066 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambroxol, 3 x 30 mg for 7 days
Number of subjects: 0
Study 3449066 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelomyrtol forte, 4 x 1 capsule (1 capsule = 0.3 g Myrtol, standardized to at least 20 mg of alpha-pinene, 75 mg of limonene, and 75 mg of cineole) for 7 days
Number of subjects: 0
Study 29475197 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy regimens
Number of subjects: 0
Study 29475197 — intervention group
Group type: EXPERIMENTAL
Intervention: Choi criteria for tumour response
Number of subjects: 0
Study 29475197 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of distant metastasis (DM)
Number of subjects: 0
Study 27619632 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 256
Study 27619632 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 256
Study 24976097 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy ± intrasinus thrombolysis (MT ± IST)
Number of subjects: 63
Study 24976097 — intervention group
Group type: COMPARATOR
Intervention: Intrasinus thrombolysis (IST) alone
Number of subjects: 63
Study 23134522 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS 30 mg plus valsartan 80 mg (N + V)
Number of subjects: 359
Study 23134522 — intervention group
Group type: COMPARATOR
Intervention: High-dose valsartan (160 mg) monotherapy (V160)
Number of subjects: 359
Study 20831738 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentists received background information about the patient prior to the dental visit (n = 29)
Number of subjects: 57
Study 20831738 — intervention group
Group type: COMPARATOR
Intervention: Dentists did not receive background information about the patient prior to the dental visit (n = 28)
Number of subjects: 57
Study 19026302 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg plus ezetimibe 10 mg
Number of subjects: 196
Study 19026302 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg
Number of subjects: 196
Study 15808114 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT with modified Dermatophagoides pteronyssinus 100 % allergen vaccine (n = 25)
Number of subjects: 50
Study 15808114 — intervention group
Group type: COMPARATOR
Intervention: Control group (pharmacological treatment only, n = 25)
Number of subjects: 50
Study 14506330 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide (100 mg, 3 times/day for 7 days before surgery)
Number of subjects: 30
Study 14506330 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 1 - distal gastrectomy with D2 lymph node dissection)
Number of subjects: 30
Study 14506330 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 3 - laparoscopy-assisted distal gastrectomy with D1 lymph node dissection)
Number of subjects: 30
Study 12748215 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 10
Study 12748215 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol CR/XL
Number of subjects: 10
Study 9607389 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (10 to 20 mg daily orally)
Number of subjects: 54
Study 9607389 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (25 to 50 mg daily orally)
Number of subjects: 54
Study 9607389 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 54
Study 7614147 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 64
Study 7614147 — intervention group
Group type: COMPARATOR
Intervention: Glass ionomer cement
Number of subjects: 64
Study 2650581 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg daily
Number of subjects: 270
Study 2650581 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 40 mg daily
Number of subjects: 270
Study 2650581 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 80 mg daily
Number of subjects: 270
Study 2650581 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (once daily)
Number of subjects: 270
Study 2650581 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 842526 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 9.1 hours (women)
Number of subjects: 41
Study 842526 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 16.5 hours (women)
Number of subjects: 41
Study 842526 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 16 hours (both sexes)
Number of subjects: 41
Study 842526 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 9 hours (men)
Number of subjects: 41
Study 842526 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 9 hours (women)
Number of subjects: 41
Study 842526 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting duration (both sexes)
Number of subjects: 41
Study 842526 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (both sexes)
Number of subjects: 41
Study 31266460 — intervention group
Group type: EXPERIMENTAL
Intervention: Online genetic education with pre- and post-test telephone genetic counseling
Number of subjects: 3000
Study 31266460 — intervention group
Group type: COMPARATOR
Intervention: Online genetic education with optional telephone counseling
Number of subjects: 3000
Study 31266460 — intervention group
Group type: COMPARATOR
Intervention: Online genetic education with required pre-test telephone genetic counseling
Number of subjects: 3000
Study 31266460 — intervention group
Group type: COMPARATOR
Intervention: Online genetic education with required post-test telephone genetic counseling
Number of subjects: 3000
Study 28396108 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented nurse care management intervention
Number of subjects: 130
Study 28396108 — intervention group
Group type: COMPARATOR
Intervention: Usual late-stage CKD care
Number of subjects: 130
Study 25500919 — intervention group
Group type: EXPERIMENTAL
Intervention: Father‐Infant Interaction Program (FIIP) - a video‐modeled play intervention
Number of subjects: 85
Study 25500919 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 85
Study 22809664 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (60/80/100 mg based on birth weight)
Number of subjects: 123
Study 22809664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 21336727 — intervention group
Group type: EXPERIMENTAL
Intervention: VitalStim therapy plus conventional swallowing training
Number of subjects: 120
Study 21336727 — intervention group
Group type: COMPARATOR
Intervention: Conventional swallowing therapy
Number of subjects: 120
Study 21336727 — intervention group
Group type: COMPARATOR
Intervention: VitalStim therapy
Number of subjects: 120
Study 19539116 — intervention group
Group type: EXPERIMENTAL
Intervention: Real cervical manipulation + real amitriptyline
Number of subjects: 19
Study 19539116 — intervention group
Group type: EXPERIMENTAL
Intervention: Real cervical manipulation + placebo amitriptyline
Number of subjects: 19
Study 19539116 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham cervical manipulation + real amitriptyline
Number of subjects: 19
Study 19539116 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham cervical manipulation + placebo amitriptyline
Number of subjects: 19
Study 16918888 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg/day)
Number of subjects: 100
Study 16918888 — intervention group
Group type: COMPARATOR
Intervention: Famotidine (40 mg/day)
Number of subjects: 100
Study 15306150 — intervention group
Group type: COMPARATOR
Intervention: Normal blood donors (ND)
Number of subjects: 600
Study 15306150 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with venous thrombosis (VT)
Number of subjects: 600
Study 10654038 — intervention group
Group type: EXPERIMENTAL
Intervention: OGA L film using Lanex Regular screens (Lanex group)
Number of subjects: 200
Study 10654038 — intervention group
Group type: COMPARATOR
Intervention: Ultra‐Vision film and screens (Ultra-vision group)
Number of subjects: 200
Study 9299800 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine alone
Number of subjects: 76
Study 9299800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy alone
Number of subjects: 76
Study 9299800 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fluoxetine and cognitive behavior therapy
Number of subjects: 76
Study 9299800 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or waiting list)
Number of subjects: 76
Study 8345004 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate 3000 mg
Number of subjects: 9
Study 8345004 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate 2000 mg
Number of subjects: 9
Study 8345004 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate 1000 mg
Number of subjects: 9
Study 8345004 — intervention group
Group type: EXPERIMENTAL
Intervention: Total drug concentration above 100 mg/l
Number of subjects: 9
Study 8345004 — intervention group
Group type: EXPERIMENTAL
Intervention: Total plasma clearance (Cl)
Number of subjects: 9
Study 8345004 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic plasma clearance (Clu)
Number of subjects: 9
Study 29092079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal benzhydrocodone API (13.34 mg)
Number of subjects: 51
Study 29092079 — intervention group
Group type: COMPARATOR
Intervention: Intranasal hydrocodone bitartrate API (15.0 mg)
Number of subjects: 51
Study 26365330 — intervention group
Group type: EXPERIMENTAL
Intervention: 15‐mg zinc sulfate daily from the 16th week of gestation until delivery
Number of subjects: 540
Study 26365330 — intervention group
Group type: COMPARATOR
Intervention: No zinc supplementation (control group)
Number of subjects: 540
Study 26365330 — intervention group
Group type: EXPERIMENTAL
Intervention: 15‐mg zinc sulfate
Number of subjects: 540
Study 24210923 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrostomy tube (G-tube) feeding
Number of subjects: 432
Study 24210923 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube (N-tube) feeding
Number of subjects: 432
Study 24210923 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral only feeding
Number of subjects: 432
Study 22658359 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole in addition to DMARD therapy
Number of subjects: 0
Study 22658359 — intervention group
Group type: COMPARATOR
Intervention: Standard DMARD therapy plus placebo
Number of subjects: 0
Study 20551499 — intervention group
Group type: EXPERIMENTAL
Intervention: GPAQ
Number of subjects: 251
Study 20551499 — intervention group
Group type: COMPARATOR
Intervention: IPAQ
Number of subjects: 251
Study 18681789 — intervention group
Group type: COMPARATOR
Intervention: 50 mg clomiphene citrate plus placebo (n = 209)
Number of subjects: 626
Study 18681789 — intervention group
Group type: COMPARATOR
Intervention: 2 g extended-release metformin plus placebo (n = 208)
Number of subjects: 626
Study 18681789 — intervention group
Group type: COMPARATOR
Intervention: Combination of metformin and clomiphene (n = 209)
Number of subjects: 626
Study 18681789 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin XR (2 g/day)
Number of subjects: 626
Study 16402651 — intervention group
Group type: EXPERIMENTAL
Intervention: Septoplasty alone
Number of subjects: 26
Study 16402651 — intervention group
Group type: COMPARATOR
Intervention: Septoplasty plus endoscopic sinus surgery
Number of subjects: 26
Study 14640057 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective COX-2 inhibitors
Number of subjects: 0
Study 14640057 — intervention group
Group type: COMPARATOR
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 10397521 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% minocycline ointment
Number of subjects: 104
Study 10397521 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 104
Study 8934149 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 0
Study 8934149 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg nicotine gum)
Number of subjects: 0
Study 1676411 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower oil emulsion
Number of subjects: 0
Study 1676411 — intervention group
Group type: EXPERIMENTAL
Intervention: 50:50 mixture of safflower and soybean oils
Number of subjects: 0
Study 1676411 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil emulsion
Number of subjects: 0
Study 6364951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin
Number of subjects: 169
Study 6364951 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 169
Study 6364951 — intervention group
Group type: COMPARATOR
Intervention: Metamizol
Number of subjects: 169
Study 31310297 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible visitation (up to 12 hours per day)
Number of subjects: 1685
Study 31310297 — intervention group
Group type: COMPARATOR
Intervention: Restricted visitation (median, 1.5 hours per day)
Number of subjects: 1685
Study 31310297 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible visitation
Number of subjects: 1685
Study 31310297 — intervention group
Group type: COMPARATOR
Intervention: Restricted visitation
Number of subjects: 1685
Study 29909019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (130 mg or 6 mg/kg intravenous)
Number of subjects: 334
Study 29909019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (subcutaneous 90 mg every 12 weeks or 8 weeks)
Number of subjects: 334
Study 29909019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study 26831676 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided PDT
Number of subjects: 118
Study 26831676 — intervention group
Group type: COMPARATOR
Intervention: Bronchoscopy-guided PDT
Number of subjects: 118
Study 25275724 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA E2 therapeutic vaccine (10^7 virus particles injected directly into uterus, urethra, vulva, or anus)
Number of subjects: 1356
Study 22797511 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer
Number of subjects: 85
Study 22797511 — intervention group
Group type: EXPERIMENTAL
Intervention: Autumn
Number of subjects: 85
Study 22797511 — intervention group
Group type: EXPERIMENTAL
Intervention: Winter
Number of subjects: 85
Study 22797511 — intervention group
Group type: EXPERIMENTAL
Intervention: Spring
Number of subjects: 85
Study 19363022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (100 mg intramuscular injections at baseline and 6 weeks)
Number of subjects: 83
Study 19363022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 16378563 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Practitioner Consultations
Number of subjects: 36
Study 11927515 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEEs) 0.625 mg
Number of subjects: 28
Study 11927515 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Number of subjects: 28
Study 11927515 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CEEs and simvastatin
Number of subjects: 28
Study 10319000 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual endoscopy (VE)
Number of subjects: 21
Study 10319000 — intervention group
Group type: COMPARATOR
Intervention: Bronchoscopy
Number of subjects: 21
Study 7500130 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily 2‐h manual practice sessions for 5 days
Number of subjects: 0
Study 7500130 — intervention group
Group type: COMPARATOR
Intervention: Control group 1: Daily TMS mapping without piano practice
Number of subjects: 0
Study 7500130 — intervention group
Group type: COMPARATOR
Intervention: Control group 2: Played the piano at will for 2 h each day using only the right hand without specific skill learning
Number of subjects: 0
Study 2613427 — intervention group
Group type: COMPARATOR
Intervention: Very low calorie diet alone
Number of subjects: 76
Study 2613427 — intervention group
Group type: COMPARATOR
Intervention: Behavior therapy alone
Number of subjects: 76
Study 2613427 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (very low calorie diet + behavior therapy)
Number of subjects: 76
Study 773495 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole and aspirin (given by mouth from the evening before operation and for seven days after operation)
Number of subjects: 160
Study 773495 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment specified)
Number of subjects: 160
Study 31842127 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid treatment
Number of subjects: 497
Study 31842127 — intervention group
Group type: COMPARATOR
Intervention: Non-acetylsalicylic acid treatment
Number of subjects: 497
Study 31842127 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative bleeding
Number of subjects: 497
Study 31842127 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 497
Study 30355861 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 215
Study 30355861 — intervention group
Group type: COMPARATOR
Intervention: FS-LASIK
Number of subjects: 215
Study 26769332 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB039110 100 mg once daily
Number of subjects: 50
Study 26769332 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB039110 200 mg once daily
Number of subjects: 50
Study 26769332 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB039110 200 mg twice daily
Number of subjects: 50
Study 26769332 — intervention group
Group type: EXPERIMENTAL
Intervention: INCB039110 600 mg once daily
Number of subjects: 50
Study 26769332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 25171502 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg (TAM) + Solifenacin 5 mg (SOL)
Number of subjects: 280
Study 25171502 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg (TAM)
Number of subjects: 280
Study 22617536 — intervention group
Group type: EXPERIMENTAL
Intervention: En bloc resection for HCC extending to adjacent organs
Number of subjects: 168
Study 22617536 — intervention group
Group type: COMPARATOR
Intervention: Control group (HCC without adjacent organ extension)
Number of subjects: 168
Study 20509073 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy with personal imagery preferences for coolness
Number of subjects: 51
Study 17618427 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid 200 mg t.i.d. for 3 days
Number of subjects: 10
Study 17618427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15908834 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) at doses of 0.45 mg/h, 0.9 mg/h, and 1.8 mg/h
Number of subjects: 36
Study 15908834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15908834 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS)
Number of subjects: 36
Study 11842306 — intervention group
Group type: EXPERIMENTAL
Intervention: Children from eastern Germany
Number of subjects: 12501
Study 11842306 — intervention group
Group type: COMPARATOR
Intervention: Children from western Germany
Number of subjects: 12501
Study 10469092 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated caffeine-based cream (higher concentration)
Number of subjects: 41
Study 10469092 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated caffeine-based cream (lower concentration)
Number of subjects: 41
Study 10469092 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 41
Study 7605021 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 545
Study 7605021 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 545
Study 2153719 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nedocromil sodium
Number of subjects: 22
Study 2153719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7018644 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 0.5 mg/kg (n = 43)
Number of subjects: 159
Study 7018644 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine 0.5 mg/kg (n = 40)
Number of subjects: 159
Study 7018644 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 0.1 mg/kg (n = 378)
Number of subjects: 159
Study 7018644 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 36)
Number of subjects: 159
Study 31898489 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Storage Root Formation and Bulking (CSRFAB)
Number of subjects: 130
Study 31898489 — intervention group
Group type: COMPARATOR
Intervention: Discontinuous Storage Root Formation and Bulking (DSRFAB)
Number of subjects: 130
Study 31898489 — intervention group
Group type: EXPERIMENTAL
Intervention: CSRFAB genotypes
Number of subjects: 130
Study 31898489 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth patterns of sweetpotato genotypes
Number of subjects: 130
Study 31898489 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad sense heritability of CSRFAB
Number of subjects: 130
Study 31898489 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproducibility of measurements
Number of subjects: 130